Szajda Sławomir Dariusz, Borzym-Kluczyk Małgorzata, Snarska Jadwiga, Puchalski Zbigniew, Zwierz Krzysztof
Department of Pharmaceutical Biochemistry, Medical University of Bialystok, Poland.
Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1287-98.
BACKGROUND/AIMS: Evaluation of N-acetyl-beta-D-hexosaminidase (HEX), and its isoenzymes A (HEX A) and B (HEX B) activity in blood serum and urine as potential markers of colorectal cancer.
The study was performed in blood serum and urine of 32 patients with adenocarcinoma, 6 with adenocarcinoma mucinosum of the colon, and 20 healthy people. The activity of HEX, HEX A and HEX B was determined in blood serum and urine by spectrophotometric method of Marciniak et al. The concentration of CEA was determined in blood serum by immunoenzymatic method (MEIA). The concentration of protein was assessed by the Lowry method, whereas the concentration of creatinine in urine by the Jaffe method (without deproteinization).
A significant increase in the concentration of HEX, HEX A and HEX B activity was proved in serum and urine of patients with colon adenocarcinoma. In patients with colon adenocarcinoma mucinosum, the higher activity of HEX was revealed in blood serum compared to healthy people, and the significantly higher activity of HEX and HEX B expressed as pKat/mg of creatinine, was found in urine. We observe a significant increase in the activity of HEX, HEX A and HEX B expressed in pKat/mg of creatinine was found in urine of patients bearing tumor of diameter 6.0-7.0 cm in comparison to patients with tumor of diameter 4.0-5.0 cm.
The present study results suggest that determination of HEX, HEX A and HEX B activity in blood serum and urine may be used to detect colon cancer in its early stages. However, the use of HEX, HEX A and HEX B activity in oncological diagnostics requires further studies on a larger group of patients.
背景/目的：评估血清和尿液中N-乙酰-β-D-氨基己糖苷酶（HEX）及其同工酶A（HEX A）和B（HEX B）的活性，将其作为结直肠癌的潜在标志物。
对32例腺癌患者、6例结肠黏液腺癌患者和20名健康人的血清和尿液进行了研究。采用Marciniak等人的分光光度法测定血清和尿液中HEX、HEX A和HEX B的活性。采用免疫酶法（MEIA）测定血清中癌胚抗原（CEA）的浓度。采用Lowry法评估蛋白质浓度，而采用Jaffe法（无需去蛋白）测定尿液中肌酐的浓度。
结肠腺癌患者的血清和尿液中HEX、HEX A和HEX B活性浓度显著升高。在结肠黏液腺癌患者中，血清中HEX活性高于健康人，尿液中以肌酐pKat/mg表示的HEX和HEX B活性显著更高。我们观察到，与直径4.0 - 5.0 cm肿瘤患者相比，直径6.0 - 7.0 cm肿瘤患者尿液中以肌酐pKat/mg表示的HEX、HEX A和HEX B活性显著增加。
本研究结果表明，测定血清和尿液中HEX、HEX A和HEX B的活性可用于早期检测结肠癌。然而，在肿瘤诊断中使用HEX、HEX A和HEX B活性需要对更大规模的患者群体进行进一步研究。
